why choose us

First received: July 20, 2022

Clinical Trial: A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants

Study Status: Completed

Recruit Status: Completed

Condition: Healthy

Study Type: Interventional


Official Title: An Open-Label, Fixed-Sequence Study to Evaluate the Effect of Multiple Doses of LOXO-292 on the Single Dose Pharmacokinetics of Repaglinide in Healthy Adult Subjects

Brief Summary: The main purpose of this study is to assess the effect of selpercatinib on how fast repaglinide gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study will last up to 12 days.

Read more